Armis Advisers »

Halozyme Therapeutics shares owned by Armis Advisers

Quarter-by-quarter ownership of Halozyme Therapeutics (HALO) shares owned by Armis Advisers from 13F filings

Historical chart of Armis Advisers investment in Halozyme Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Halozyme Therapeutics held by Armis Advisers consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Halozyme Therapeutics by Armis Advisers

Quarter filed Position value Share count Share price at filing
2024-12-31 $295k 6.2k 47.81

More positions owned by Armis Advisers

Listed Fds Tr Shares Lag Cap (OVL)
Vanguard Index Fds Total Stk Mkt (VTI)
Vanguard Tax-managed Fds Van Ftse Dev Mkt (VEA)
Listed Fds Tr Overlay Shares (OVLH)
Vanguard Index Fds Growth Etf (VUG)
Listed Fds Tr Overlay Shs Shrt (OVT)
Spdr S&p 500 Etf Tr Tr Unit (SPY)
Invesco Qqq Tr Unit Ser 1 (QQQ)
Apple (AAPL)
Ishares Tr Rus 1000 Grw Etf (IWF)
Pacer Fds Tr Swan Sos Fd Of (PSFF)
Vanguard Index Fds Value Etf (VTV)
Microsoft Corporation (MSFT)
NVIDIA Corporation (NVDA)
Vanguard World Mega Cap Val Etf (MGV)

View all positions for Armis Advisers

Top funds holding Halozyme Therapeutics

BlackRock
Vanguard Group
State Street Corporation
Arrowstreet Capital, Limited Partnership
Invesco
Snyder Capital Management
D. E. Shaw & Co
Geode Capital Management
Dimensional Fund Advisors
Alliancebernstein
Macquarie Group
Federated Investors
Hanna Zanoni
UBS Group
Two Sigma Investments

View all funds holding Halozyme Therapeutics